Interpace Diagnostics Announces US Patent Approval: MicroRNAs as Biomarkers for Distinguishing Benign From Malignant Thyroid Neoplasms

Interpace Biosciences, Inc. recently announced the United States Patent and Trademark Office granted it a Patent (US PTO Number 11,118,231 B2) for use of microRNAs for distinguishing benign from malignant thyroid neoplasms. This patent covers the underlying technology of its ThyraMIR microRNA Classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of proteins involved in human cancers, including thyroid cancer.

ThyraMIR, a micro-RNA classifier, is designed to work in concert with Interpace’s NGS based ThyGeNEXT test to risk stratify indeterminate Thyroid nodules. By measuring the expression levels of 10 microRNAs, ThyraMIR, in combination with ThyGeNEXT provide actionable rule-in and rule-out results, reducing unnecessary Thyroidectomy surgeries and improving patient care.

Alidad Mireskandari, PhD, MBA, Chief Development Officer of Interpace Biosciences, said “We are pleased to announce the approval of this patent by the US PTO. This patent adds to our existing portfolio of Intellectual Property that protects our innovative products and unique technology around the use of micro RNAs as key diagnostic analytes.”

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has five commercialized molecular tests and one test in a clinical evaluation program (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA, a “molecular only” version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN, a molecular based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a clinical evaluation program (CEP) whereby we gather information from physicians using BarreGEN to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, while also improving patient care. For more information, visit  www.interpace.com.